You are here:Home-Research Areas-Infection-HBV Infection

Request The Product List ofHBV Infection HBV Infection

Cat. No. Product Name CAS No. Information

NVR 3-778


NVR 3-778 (NVR3-778, NVR 3778) is a small molecule inhibitor of HBV replication that targets the viral core protein, a first-in-class capsid assembly modulator; inhibits the generation of infectious HBV DNA containing virus particles with EC50 of 0.40 uM in HepG2.2.15 cells; NVR 3-778 inhibits pgRNA encapsidation, viral replication and the production of HBV DNA- and HBV RNA-containing particles, also inhibits de novo infection and viral replication in primary human hepatocytes with EC50 of 0.81 uM against HBV DNA and 3.7-4.8 uM against the production of HBV antigens and intracellular HBV RNA; demonstrates favorable pharmacokinetics and safety in animal species.

HBV Infection

Phase 1 Clinical




AB-423 is a novel potent, class II HBV capsid inhibitor that shows potent inhibition of HBV replication with EC50 of 0.08-0.27 uM, with no significant cytotoxicity (CC50>10 uM); inhibits HBV genotypes A through D and nucleos/tide-resistant variants, causes capsid particles devoid of encapsidated pgRNA and rcDNA in treated HepDES19 cells, prevents the conversion of encapsidated rcDNA to cccDNA presumably by interfering with the capsid uncoating process; dose-dependently reduces serum HBV DNA levels in mouse model of HBV model, shows synergistic antiviral activity combined with entecavir (ETV).

HBV Infection

Phase 1 Clinical


Inarigivir soproxil


Inarigivir soproxil (SB-9200, SB9200, Inarigivir, ORI-9020) is an orally bioavailable dinucleotide that activates RIG-I and NOD2, induces interferon mediated antiviral immune responses; shows broad-spectrum antiviral activity against RNA viruses including HCV, norovirus, RSV and influenza, and also demonstrates activity HBV in vitro and in vivo; a novel agonist of innate immunity, and prodrug of Inarigivir (ORI-9020;SB-9000).

HBV Infection

Phase 2 Clinical



960527-22-4 Isothiafludine (NZ-4) is a novel HBV capsid assembly inhibitor that inhibits HBV replication through blocking pregenomic RNA encapsidation, suppresses HBV replication in HepG2.2.15 cells with IC50 of 1.33 uM; shows activity against the replication of various drug-resistant HBV mutants, including 3TC/ETV-dual-resistant and ADV-resistant HBV mutants; concentration-dependently reduces the encapsidated HBV pgRNA, resulting in the assembly of replication-deficient capsids in HepG2.2.15 cells; inhibits DHBV DNA replication in the DHBV-infected ducks after oral administration.

HBV Infection

Phase 1 Clinical



1092970-12-1 GLS4 (Morphothiadin) is a potent inhibitor of HBV capsid assembly, inhibits HBV replication (EC50=62.24 nM) and reduces HBV-DNA levels in HepG.2.2.15 cells (IC50=14 nM), shows efficacy against ADV-resistant HBV mutations; strongly inhibits core gene expression (at 100 to 200 nM), suppresses virus accumulation in the supernantant of HepAD38 cells; inhibits HBV replicative forms in the live, shows strong and sustained suppression of virus DNA in treated mice.

HBV Infection

Phase 3 Clinical



441785-26-8 Besifovir (PMCDG Dipivoxil, NA-380, LB-80380) is a potent, selective, orally available anti-HBV agent, the prodrug of PMCDG (EC50=4 uM).

HBV Infection

Phase 3 Clinical



1578153-27-1 RO6889678 is a highly potent inhibitor of HBV capsid formation with attributes that are favorable for targeting the liver, whilst maintaining moderate peripheral exposure.

HBV Infection

Phase 1 Discontinued

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us